| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1017531157 |
| P356 | DOI | 10.1007/S00213-012-2921-8 |
| P698 | PubMed publication ID | 23179966 |
| P50 | author | Andrea de Bartolomeis | Q42961470 |
| P2093 | author name string | F Iasevoli | |
| E F Buonaguro | |||
| P2860 | cites work | The dopamine hypothesis of schizophrenia: version III--the final common pathway | Q22242827 |
| An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior | Q24310712 | ||
| F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia. | Q24564963 | ||
| G-protein-coupled receptor heterodimerization modulates receptor function | Q24603239 | ||
| Group II metabotropic glutamate receptor agonist ameliorates MK801-induced dysfunction of NMDA receptors via the Akt/GSK-3β pathway in adult rat prefrontal cortex | Q24612550 | ||
| Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors | Q24630429 | ||
| Building a new conceptual framework for receptor heteromers | Q24644975 | ||
| Identification of a serotonin/glutamate receptor complex implicated in psychosis | Q24655484 | ||
| Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models | Q28119018 | ||
| Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors | Q28140916 | ||
| Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release | Q28142342 | ||
| Mutation screening of the Homer gene family and association analysis in schizophrenia | Q28180472 | ||
| A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain | Q28211993 | ||
| SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity | Q28262782 | ||
| Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex | Q28264575 | ||
| Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization | Q28267111 | ||
| Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats | Q28280906 | ||
| Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior | Q28286238 | ||
| Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist | Q28296508 | ||
| Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo | Q28512114 | ||
| Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype | Q28569264 | ||
| Methylation of the CpG sites only on the sense strand of the APC gene is specific for hepatocellular carcinoma | Q28743228 | ||
| Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring | Q28754716 | ||
| Cell Permeable Peptides: A Promising Tool to Deliver Neuroprotective Agents in the Brain | Q30437957 | ||
| The presynaptic component of the serotonergic system is required for clozapine's efficacy. | Q30471071 | ||
| A phenomenological comparison of LSD and schizophrenic states. | Q52250605 | ||
| Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. | Q52506986 | ||
| Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. | Q53444102 | ||
| A comparison of the acute effects of zotepine and other antipsychotics on rat cortical dopamine release, in vivo. | Q54352495 | ||
| Regulation of Akt and Wnt signaling by the group II metabotropic glutamate receptor antagonist LY341495 and agonist LY379268. | Q54597890 | ||
| Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values | Q69374550 | ||
| "Psychedelic" Experiences in Acute Psychoses | Q72779740 | ||
| Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study | Q73144735 | ||
| Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice | Q73276377 | ||
| Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients | Q73719191 | ||
| Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area | Q73763841 | ||
| Endogenous serotonin enhances the release of dopamine in the striatum only when nigro-striatal dopaminergic transmission is activated | Q74238236 | ||
| A two-year evaluation of chlorpromazine in clinical research and practice | Q74284277 | ||
| Pharmacological characterizations of memantine-induced disruption of prepulse inhibition of the acoustic startle response in mice: involvement of dopamine D2 and 5-HT2A receptors | Q82734499 | ||
| Attention deficit induced by blockade of N-methyl D-aspartate receptors in the prefrontal cortex is associated with enhanced glutamate release and cAMP response element binding protein phosphorylation: role of metabotropic glutamate receptors 2/3 | Q83067494 | ||
| Hallucinogenic drug induced states resemble acute endogenous psychoses: results of an empirical study | Q84447367 | ||
| Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors | Q39657147 | ||
| A cyclic peptide targeted against PSD-95 blocks central sensitization and attenuates thermal hyperalgesia | Q39908449 | ||
| Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. | Q40072204 | ||
| Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activity via calmodulin kinase II-NMDA receptor interactions. | Q40226041 | ||
| KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia | Q40363514 | ||
| A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression | Q40485025 | ||
| Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex | Q40629393 | ||
| A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction | Q40654414 | ||
| M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats | Q41615477 | ||
| Mechanism of activation and function of protein kinase B. | Q41732739 | ||
| Blockade of nucleus accumbens 5-HT2A and 5-HT2C receptors prevents the expression of cocaine-induced behavioral and neurochemical sensitization in rats | Q41876191 | ||
| Chronic antidepressants induce redistribution and differential activation of alphaCaM kinase II between presynaptic compartments. | Q42171463 | ||
| Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. | Q42171479 | ||
| Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice | Q42500923 | ||
| Characterization of the proteome, diseases and evolution of the human postsynaptic density. | Q42610204 | ||
| Effect of tandospirone, a serotonin-1A receptor partial agonist, on information processing and locomotion in dizocilpine-treated rats | Q42949866 | ||
| Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole | Q42961384 | ||
| Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions | Q43122987 | ||
| Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first- and second-generation antipsychotics: effect of short-term drug discontinuation and comparison with Homer1a-interacting genes | Q43165997 | ||
| Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat. | Q43242125 | ||
| Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance | Q43275264 | ||
| Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. | Q43283706 | ||
| Effect of clozapine on the dimerization of serotonin 5-HT(2A) receptor and its genetic variant 5-HT(2A)H425Y with dopamine D(2) receptor | Q43555535 | ||
| The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability | Q43842117 | ||
| Acute administration of antipsychotics modulates Homer striatal gene expression differentially | Q43880337 | ||
| The selective serotonin(1A)-receptor antagonist WAY 100635 blocks behavioral stimulating effects of cocaine but not ventral striatal dopamine increase | Q44111455 | ||
| Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients | Q44182405 | ||
| Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions | Q44193907 | ||
| Clozapine-induced reduction of glutamate transport in the frontal cortex is not mediated by GLAST and EAAC1. | Q44295851 | ||
| Regulation of PI3K/Akt signaling by N-desmethylclozapine through activation of δ-opioid receptor | Q44350433 | ||
| Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration | Q44374196 | ||
| The 5-HT2A receptor antagonist M100,907 attenuates motor and 'impulsive-type' behaviours produced by NMDA receptor antagonism | Q44540861 | ||
| Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice | Q44654536 | ||
| The difference between the experienced reality of hallucinations in young drug abusers and schizophrenic patients | Q44677537 | ||
| Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia | Q44743796 | ||
| Metabotropic glutamate 2/3 receptors as drug targets | Q44798168 | ||
| Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies | Q44849193 | ||
| AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test | Q45021524 | ||
| Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats | Q45037369 | ||
| Antidepressants activate CaMKII in neuron cell body by Thr286 phosphorylation | Q45217305 | ||
| Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum | Q45287391 | ||
| Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats. | Q45970112 | ||
| Complex, multimodal behavioral profile of the Homer1 knockout mouse. | Q45990816 | ||
| Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia--a postmortem study. | Q46039002 | ||
| Dopamine receptor subtypes contribution to Homer1a induction: insights into antipsychotic molecular action | Q46109007 | ||
| Antipsychotic and antidepressant co-treatment: effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders | Q46135298 | ||
| Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study | Q46397161 | ||
| Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin | Q46411318 | ||
| The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating | Q46429862 | ||
| Analysis of the role of 5-HT1A receptors in spatial and aversive learning in the rat. | Q46436815 | ||
| Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology | Q46438539 | ||
| Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors | Q46446352 | ||
| 5-HT2A and muscarinic receptors in schizophrenia: a postmortem study | Q46447717 | ||
| PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors | Q30482703 | ||
| LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor | Q30484494 | ||
| Role of serotonin 2A receptors in the D-amphetamine-induced release of dopamine: comparison with previous data on alpha1b-adrenergic receptors | Q30965915 | ||
| On the fitting of binding data when receptor dimerization is suspected | Q31158245 | ||
| 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release | Q32134744 | ||
| Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. | Q33186255 | ||
| Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages | Q33606027 | ||
| The role of serotonin in antipsychotic drug action | Q33702888 | ||
| Abnormalities in α/β-CaMKII and related mechanisms suggest synaptic dysfunction in hippocampus of LPA1 receptor knockout mice. | Q33717636 | ||
| Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? | Q33812982 | ||
| An animal model of schizophrenia based on chronic LSD administration: old idea, new results | Q33830284 | ||
| Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex | Q33884206 | ||
| 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex | Q33912242 | ||
| Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group | Q33958613 | ||
| Practice guideline for the treatment of patients with schizophrenia, second edition. | Q33976372 | ||
| Association between AKT1 but not AKTIP genetic variants and increased risk for suicidal behavior in bipolar patients. | Q34096914 | ||
| Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs | Q34192438 | ||
| Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. | Q34236107 | ||
| Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia | Q34272454 | ||
| Diverse psychotomimetics act through a common signaling pathway | Q34278280 | ||
| Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. | Q34310093 | ||
| GSK3 takes centre stage more than 20 years after its discovery | Q34374129 | ||
| Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo | Q34402623 | ||
| Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers | Q34475011 | ||
| Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action | Q34485906 | ||
| DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia | Q34508840 | ||
| Lifetime prevalence of psychotic and bipolar I disorders in a general population | Q34596831 | ||
| DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in schizophrenic patients--support for the glutamate hypothesis of schizophrenias | Q34617115 | ||
| A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis | Q34631718 | ||
| Treatment with olanzapine is associated with modulation of the default mode network in patients with Schizophrenia | Q34660641 | ||
| Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells | Q34693656 | ||
| Interactive effects of mGlu5 and 5-HT2A receptors on locomotor activity in mice | Q34770846 | ||
| Molecular biology of 5-HT receptors | Q34788155 | ||
| Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat. | Q34791678 | ||
| Opposite effects of PSD-95 and MPP3 PDZ proteins on serotonin 5-hydroxytryptamine2C receptor desensitization and membrane stability | Q35128324 | ||
| Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease | Q35603265 | ||
| Postsynaptic density scaffolding proteins at excitatory synapse and disorders of synaptic plasticity: implications for human behavior pathologies. | Q35684713 | ||
| GPCR-interacting proteins (GIPs): nature and functions | Q35922926 | ||
| Elevated dopa decarboxylase activity in living brain of patients with psychosis | Q35927690 | ||
| Chronic treatment with lithium or valproate modulates the expression of Homer1b/c and its related genes Shank and Inositol 1,4,5-trisphosphate receptor. | Q35992454 | ||
| In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain | Q36002807 | ||
| Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method | Q36050571 | ||
| Principles: a model for the allosteric interactions between ligand binding sites within a dimeric GPCR. | Q36157407 | ||
| Akt as a mediator of cell death | Q36161549 | ||
| Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. | Q36296703 | ||
| Break on through to the other side-biophysics and cell biology shed light on cell-penetrating peptides | Q36299512 | ||
| The postsynaptic density | Q36545830 | ||
| Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation | Q36687682 | ||
| Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development | Q36756374 | ||
| Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile | Q36798643 | ||
| Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. | Q36870038 | ||
| The nature of dopamine dysfunction in schizophrenia and what this means for treatment | Q37062793 | ||
| Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. | Q37092462 | ||
| In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems | Q37260898 | ||
| Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia | Q37329216 | ||
| Protein-protein interactions as therapeutic targets in neuropsychopharmacology | Q37349672 | ||
| The 'atypicality' of antipsychotics: a concept re-examined and re-defined | Q37391972 | ||
| Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade | Q37416273 | ||
| Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes | Q37515921 | ||
| Antipsychotic drug actions on gene modulation and signaling mechanisms | Q37525390 | ||
| Serotonin 2A receptor antagonists for treatment of schizophrenia | Q37899193 | ||
| Glutamatergic transmission in schizophrenia: from basic research to clinical practice | Q37980657 | ||
| Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia. | Q37990329 | ||
| A frontier in the understanding of synaptic plasticity: solving the structure of the postsynaptic density. | Q38005085 | ||
| Calcium-dependent networks in dopamine-glutamate interaction: the role of postsynaptic scaffolding proteins. | Q38024032 | ||
| Scaffolding proteins of the post-synaptic density contribute to synaptic plasticity by regulating receptor localization and distribution: relevance for neuropsychiatric diseases | Q38044699 | ||
| Acute Effects of Ketamine on Memory Systems and Psychotic Symptoms in Healthy Volunteers | Q38425577 | ||
| Dopamine D2 and 5-hydroxytryptamine 5-HT(₂A) receptors assemble into functionally interacting heteromers. | Q39648976 | ||
| Serotonin 5-HT1A receptors regulate NMDA receptor channels through a microtubule-dependent mechanism. | Q46535519 | ||
| Role of 5-HT2A and 5-HT2C/B receptors in the acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on striatal single-unit activity and locomotion in freely moving rats | Q46587077 | ||
| Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: implications for Tourette's syndrome | Q46620328 | ||
| The effects of antipsychotics on beta-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats | Q46689005 | ||
| 5-Hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms | Q46751918 | ||
| Distinct roles for different Homer1 isoforms in behaviors and associated prefrontal cortex function. | Q46851475 | ||
| Stress-induced dopamine release in humans at risk of psychosis: a [11C]raclopride PET study | Q46934815 | ||
| Chronic phenethylamine hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor agonist | Q46934817 | ||
| Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study | Q46943015 | ||
| Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action | Q46966416 | ||
| Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative | Q48102710 | ||
| Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum | Q48104853 | ||
| Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. | Q48121459 | ||
| The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats | Q48137014 | ||
| The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task | Q48185891 | ||
| Inhibition of glycogen synthase kinase-3 attenuates psychotomimetic effects of ketamine | Q48187914 | ||
| Differential expression of Homer 1 gene by acute and chronic administration of antipsychotics and dopamine transporter inhibitors in the rat forebrain | Q48234714 | ||
| Ketamine-related expression of glutamatergic postsynaptic density genes: possible implications in psychosis | Q48265498 | ||
| Association of AKT1 gene variants and protein expression in both schizophrenia and bipolar disorder | Q48278865 | ||
| Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia | Q48283671 | ||
| Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory | Q48285410 | ||
| Dual alteration of limbic dopamine D1 receptor-mediated signalling and the Akt/GSK3 pathway in dopamine D3 receptor mutants during the development of methamphetamine sensitization | Q48372061 | ||
| Haloperidol induces neurotoxicity by the NMDA receptor downstream signaling pathway, alternative from glutamate excitotoxicity. | Q48375937 | ||
| Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. | Q48390432 | ||
| Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis | Q48394255 | ||
| WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity | Q48397691 | ||
| Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion | Q48448242 | ||
| Long-term soluble Abeta1-40 activates CaM kinase II in organotypic hippocampal cultures. | Q48469484 | ||
| Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs | Q48493255 | ||
| Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. | Q48556742 | ||
| Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain | Q48629603 | ||
| Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades | Q48679393 | ||
| Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis | Q48723515 | ||
| Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex | Q48728126 | ||
| Decreased frontal cortical serotonin2A receptors in schizophrenia | Q48915737 | ||
| The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes | Q48967410 | ||
| Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. | Q49128057 | ||
| The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice | Q50313913 | ||
| Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. | Q51015703 | ||
| Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. | Q51370914 | ||
| Density of metabotropic glutamate receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex does not differ with schizophrenia diagnosis but decreases with age. | Q51601516 | ||
| Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. | Q51810340 | ||
| Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT 2A/2C receptors. | Q51905348 | ||
| Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics. | Q51976441 | ||
| Delayed alternation performance following subchronic phencyclidine administration in rats depends on task parameters. | Q51987036 | ||
| Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs. | Q52000561 | ||
| Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. | Q52033175 | ||
| 5HT antagonists attenuate MK801-impaired radial arm maze performance in rats. | Q52178014 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | serotonin | Q167934 |
| dopamine | Q170304 | ||
| P304 | page(s) | 1-19 | |
| P577 | publication date | 2012-11-21 | |
| P1433 | published in | Psychopharmacology | Q1422802 |
| P1476 | title | Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins | |
| P478 | volume | 225 |
| Q50015658 | A comprehensive review of the genetic and biological evidence supports a role for MicroRNA-137 in the etiology of schizophrenia. |
| Q35174979 | A double-blind, randomized pilot trial of chromium picolinate for binge eating disorder: results of the Binge Eating and Chromium (BEACh) study |
| Q39767786 | A heuristic model for working memory deficit in schizophrenia |
| Q38248566 | Antipsychotic treatment modulates glutamate transport and NMDA receptor expression |
| Q60229355 | Big Lessons from Tiny Flies: as a Model to Explore Dysfunction of Dopaminergic and Serotonergic Neurotransmitter Systems |
| Q59329370 | COMT, 5-HTR2A, and SLC6A4 mRNA Expressions in First-Episode Antipsychotic-Naïve Schizophrenia and Association With Treatment Outcomes |
| Q48682603 | Cane Toad Skin Extract-Induced Upregulation and Increased Interaction of Serotonin 2A and D2 Receptors via Gq/11 Signaling Pathway in CLU213 Cells |
| Q42969381 | Clozapine augmentation with amisulpride |
| Q48423771 | Clozapine influences cytoskeleton structure and calcium homeostasis in rat cerebral cortex and has a different proteomic profile than risperidone |
| Q35928195 | Dietary chromium supplementation for targeted treatment of diabetes patients with comorbid depression and binge eating |
| Q45054111 | Differences in 5-HT2A and mGlu2 Receptor Expression Levels and Repressive Epigenetic Modifications at the 5-HT2A Promoter Region in the Roman Low- (RLA-I) and High- (RHA-I) Avoidance Rat Strains. |
| Q27693888 | Drug elucidation: invertebrate genetics sheds new light on the molecular targets of CNS drugs |
| Q47412781 | GSK-3β inhibitors reverse cocaine-induced synaptic transmission dysfunction in the nucleus accumbens |
| Q38166456 | Genetics of antipsychotic-induced weight gain: update and current perspectives |
| Q38133757 | Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches. |
| Q35167939 | Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study |
| Q92082552 | Intra-Nasally Administered Oligopeptide Lunasin Acts as a Possible Anti-Psychotic Agent in Mice Models |
| Q48475935 | Investigation of the role of alpha-2 adrenergic receptors on prepulse inhibition of acoustic startle reflex in rats |
| Q38267957 | MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective. |
| Q26747736 | Multiple D2 heteroreceptor complexes: new targets for treatment of schizophrenia |
| Q89896535 | N-(2-Hydroxyphenyl)-1-[3-(2-oxo-2,3-dihydro-1H- benzimidazol-1-yl)propyl]piperidine-4-Carboxamide (D2AAK4), a Multi-Target Ligand of Aminergic GPCRs, as a Potential Antipsychotic |
| Q37583157 | Neurophysiological Measures and Alcohol Use Disorder (AUD): Hypothesizing Links between Clinical Severity Index and Molecular Neurobiological Patterns |
| Q41573540 | New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis |
| Q35021488 | Olanzapine antipsychotic treatment of adolescent rats causes long term changes in glutamate and GABA levels in the nucleus accumbens |
| Q30379983 | Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end? |
| Q47706234 | Pharmacological approaches to the management of binge eating disorder |
| Q58719221 | Polymorphisms in the human serotonin receptor 1B (HTR1B) gene are associated with schizophrenia: a case control study |
| Q63433406 | Preclinical characterization of toluene as a non-classical hallucinogen drug in rats: participation of 5-HT, dopamine and glutamate systems |
| Q38258215 | Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis |
| Q26863507 | Response inhibition and interference control in obsessive-compulsive spectrum disorders |
| Q35118239 | Ribosomal DNA transcription in the dorsal raphe nucleus is increased in residual but not in paranoid schizophrenia |
| Q38223390 | Serotoninergic and dopaminergic modulation of cortico-striatal circuit in executive and attention deficits induced by NMDA receptor hypofunction in the 5-choice serial reaction time task |
| Q33685248 | Superior effects of quetiapine compared with aripiprazole and iloperidone on MK-801-induced olfactory memory impairment in female mice |
| Q92259371 | The Effect of Chromium Nanoparticles and Chromium Picolinate in the Diet of Chickens on Levels of Selected Hormones and Tissue Antioxidant Status |
| Q35405088 | The ascending median raphe projections are mainly glutamatergic in the mouse forebrain. |
| Q38213709 | The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment |
| Q30417825 | The role of cannabinoid 1 receptor expressing interneurons in behavior |
| Q30437188 | The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue |
| Q64108690 | Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates |
| Q41945244 | Two grams of sarcosine in schizophrenia - is it too much? A potential role of glutamate-serotonin interaction. |
| Q36300230 | Understanding the Role of GPCR Heteroreceptor Complexes in Modulating the Brain Networks in Health and Disease |
| Q28084069 | Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism |
| Q37024867 | Variation in Dopamine D2 and Serotonin 5-HT2A Receptor Genes is Associated with Working Memory Processing and Response to Treatment with Antipsychotics |
Search more.